How is GHK-Cu dosed?
Vendors sell GHK-Cu as an injectable research vial, but no human study of the injected route exists. Every human study found for this page is topical — and even that evidence is weaker than its cosmetic reputation suggests. This page reads each study directly, states its route and formulation, and never presents a topical concentration as if it said anything about an injected dose.
Topic: Reading what has actually been studied for GHK-Cu — topical only, and how strongly sourced each study really is
Audience: Anyone comparing a GHK-Cu dose figure against what was actually studied and by which route
Reading time: 8–10 minutes
No human study of injectable GHK-Cu exists
GHK-Cu has not been approved by the FDA as a drug for any route. Checked directly against ClinicalTrials.gov and PubMed, every human study found used a topical formulation — cream, serum, or gel. No completed or currently registered trial administers GHK-Cu by injection. Every figure on this page is a fact about a specific study — not a recommendation.
On this page
GHK-Cu: every human study is topical
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine, studied for effects on collagen production, wound healing, and skin appearance. It is widely sold as a cosmetic ingredient (topical) and, separately, as a research-grade injectable vial. Human clinical evidence covers only the first of those two forms — the GHK-Cu profile covers the mechanism and the animal-study evidence for systemic/injectable effects in more depth; this page exists specifically to read the human topical studies directly and keep the route distinction visible throughout.
The evidence below is ordered by design strength within the topical studies themselves — the one properly registered, ongoing RCT first, then the older studies behind GHK-Cu’s cosmetic reputation, graded honestly by how well each one is actually sourced — then community-reported injectable practice last, attributed and marked unverified, since no human study exists for that route to compare it against.
The one currently registered trial
Topical GHK-Cu Gel for Acute Skin Wound Healing
NCT07437586RECRUITING (confirmed against the live ClinicalTrials.gov API on the date this page was built); no results posted
Design: Phase 2, randomized trial testing whether a topical GHK-Cu gel speeds healing of small, standardized skin wounds in healthy adults, versus a matching vehicle gel. Participants receive two small punch-biopsy wounds on the upper arm.
Arms: 60 participants planned (estimated). GHK-Cu gel: 0.1% w/w, applied as a thin film (approximately 0.5 g) once daily for 14 days, versus a matching vehicle gel.
The only properly registered RCT-design human study of GHK-Cu found for this page — but currently recruiting, with no efficacy or safety results posted yet.
The GHK-Cu reconstitution calculator performs the arithmetic of converting a vial and reconstitution volume into syringe units for a given milligram figure; it does not set a schedule and does not imply that route has completed human trial support.
The topical studies behind the cosmetic reputation
These are the studies most often cited for GHK-Cu’s cosmetic benefits. Checked directly against PubMed, neither is indexed in MEDLINE, and one was never published as a peer-reviewed paper at all — graded accordingly, not treated as equivalent evidence to a properly indexed trial.
Badenhorst et al. 2016 — Nano-Lipid-Carrier Wrinkle Study
Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. J Aging Sci. 2016;4:166. DOI 10.4172/2329-8847.1000166.
Design: Randomized, double-blind trial in female volunteers aged 40–65 (N=40), comparing GHK-Cu encapsulated in a nano-lipid carrier, a carrier-alone control, and a commercial comparator serum (Matrixyl 3000), applied twice daily to facial skin for 8 weeks.
Outcome reported: GHK-Cu produced a 31.6% reduction in wrinkle volume compared to Matrixyl 3000 (p=0.004), and a 55.8% reduction in wrinkle volume and 32.8% reduction in wrinkle depth compared to the carrier-alone control (p<0.001, p=0.012).
A real, published, controlled trial — but not indexed in PubMed/MEDLINE, confirmed by direct search. Journal of Aging Science is an OMICS-affiliated open-access title; this page reports the finding without treating it as equivalent to a MEDLINE-indexed publication.
Leyden et al. 2002 — Facial and Eye Cream (Two Conference Presentations, Never Published)
Leyden J, et al. Presented at the American Academy of Dermatology 60th Annual Meeting, 2002. No peer-reviewed paper or PMID exists for either presentation.
Design: Two separate studies: a topical facial cream in 71 women, and a topical eye cream in 41 women, each over 12 weeks.
Outcome reported: Reported increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth — as summarized in later review articles that cite these presentations, since no original published paper exists to read directly.
Conference presentation only, never published as a peer-reviewed paper — the weakest tier of the human evidence cited for GHK-Cu, reported here as such rather than treated as a citable trial.
Is there a community-reported injectable dose?
Yes — a 30-day cycle of 1 mg/day subcutaneously for the first 15 days, then 2 mg/day for the remaining 15 days, followed by a 30-day break, is the figure consistently reported across vendor and community sources and already documented on the GHK-Cu profile. It is reported here, below the topical evidence above, as observed practice attributed to where it circulates — not derived from any human study.
There is no trial-derived injectable figure for this community dose to diverge from — that is itself the finding: the route the community protocol describes has no human study behind it at all. Topical concentrations reported in the studies above (0.1% w/w in the recruiting wound trial; 1–3% in commercial cosmetic products) describe a percentage of a topical formulation, not a milligram injected amount, and this page does not convert between the two.
Regulatory position: withdrawn from Category 2, no PCAC evaluation yet
Injectable GHK-Cu is in the same withdrawn-nomination limbo as several other compounds this site has checked; FDA has not yet published a detailed evaluation of it.
Checked directly against FDA’s own bulk-substance safety-risk page: “GHK-Cu (for injectable routes of administration)” appears in the 503A “nominated but withdrawn” table, citing immunogenicity risk and limited human safety data as the original concern. It was placed in Category 2 in 2023 and removed on April 15, 2026 on the same procedural nomination-withdrawal basis seen across several other peptides.
Unlike BPC-157, TB-500, ipamorelin, and CJC-1295 — each of which has a detailed FDA staff evaluation document already published — no PCAC briefing document for GHK-Cu was found. A committee review is reported to be scheduled before the end of February 2027; this page does not anticipate what that evaluation will conclude, since it does not exist yet. No FDA warning letter specifically naming GHK-Cu was found; two 2026 warning letters to peptide vendors Prof. Peptide tracks (Peptide Partners LLC, Royal Peptides LLC) were checked directly, and neither cites GHK-Cu among the substances named.
Topical GHK-Cu, unlike the injectable form, is not subject to this compounding framework at all — it is sold as a cosmetic ingredient, a different regulatory category entirely. Research-grade injectable GHK-Cu, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is not an approved product and is sold labeled for laboratory research use, not for human administration.
FAQ
Has injectable GHK-Cu been tested in humans?
What is the strongest human study of GHK-Cu?
Is the wrinkle-reduction study behind GHK-Cu's cosmetic reputation a strong one?
What concentration is used in topical GHK-Cu studies?
What adverse events have been reported for topical GHK-Cu?
Is there a commonly reported injectable GHK-Cu dosing protocol?
What is GHK-Cu's current FDA compounding status?
References
- ClinicalTrials.gov. Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586. https://clinicaltrials.gov/study/NCT07437586
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4:166. https://www.walshmedicalmedia.com/open-access/effects-of-ghkcu-on-mmp-and-timp-expression-collagen-and-elastin-production-and-facial-wrinkle-parameters-2329-8847-1000166.pdf
- Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Open Life Sci. 2015;10(1):111-121. (Review citing the Leyden et al. 2002 AAD conference presentations, which have no independent PMID or publication of their own.) https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
We may earn commissions from peptide vendor affiliate links.